• Publications
  • Influence
The relevance of the CD4+ CD26– subset in the identification of circulating Sézary cells
Background  The lack of specific markers for the phenotyping of circulating neoplastic T cells in Sézary syndrome (SS) patients makes it difficult both to ascertain the presence of clonal cells andExpand
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
The purpose of the present document is to update the original recommendations bearing in mind that there are still only a limited number of controlled studies to support treatment decisions for MF/SS and that often treatment is determined by institutional experience and availability. Expand
Guidelines on the use of extracorporeal photopheresis
The technology has shown significant promise in the treatment of other severe and refractory conditions in a multi‐disciplinary setting, among the major studied conditions are graft versus host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection and inflammatory bowel disease. Expand
Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
The identification of poor prognostic factors may be used to develop a prognostic index to use alongside staging, which may be of benefit in mycosis fungoides/Sézary syndrome to identify patients with a potentially poor prognosis. Expand
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
The development of cutaneous AEs, especially of hypopigmentation in patients with melanoma, could point toward better treatment response, as well as disease progression and response to pembrolizumab treatment. Expand
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
Significant improvement in objective response lasting at least 4 months was seen with brentuximab vedotin versus physician's choice of methotrexate or bexarotene in previously treated patients with CD30-positive cutaneous T-cell lymphomas. Expand
Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas.
A possiblePCBCL subclassification and the extent of cutaneous involvement as the two most relevant prognostic factors in PCBCL are identified and can be considered reasonably as the clinical background for an appropriate management strategy. Expand
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a
This study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratifyadvanced-stage patients. Expand
Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases
An expert panel drawn from a range of disciplines from dermatology, general surgery, head and neck surgery, plastic surgery, and oncology met to form a consensus opinion to update the SOPs based on the experience obtained, and contains updated recommendations for indications for electrochemotherapy. Expand
Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients.
Peripheral blood CD4(+) T cells from 59 patients with Sézary syndrome and 19 patients with erythrodermic inflammatory dermatoses were analyzed for cell surface proteins by flow cytometry and for copy number alterations and differential gene expression using custom-made quantitative PCR plates. Expand